Trial Profile
An Open-label Long-term Extension Trial From Phase III of SPM962 (243-08-002) in Advanced Parkinson's Disease Patients With Concomitant Treatment of L-dopa
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Mar 2014
Price :
$35
*
At a glance
- Drugs Rotigotine (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Registrational
- Sponsors Otsuka Pharmaceutical
- 24 Mar 2014 New trial record